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Summary To explore the clinical significance of the level
of HER2/neu gene amplification in a homogenous cohort of
33 patients with HER2-positive metastatic breast cancer
(MBC) and available tumor samples treated with a
trastuzumab-based regimen, we retrospectively performed
dual-color fluorescence in-situ hybridization test and
correlated them for each patient with time-to-progression
(TTP) and overall survival (OS). We obtained values of
HER2/chromosome 17 centromere (CEP17) ratio ranging
from 2.5 to 21 (median 7.2). At the Cox model there is
indication that patients whose tumors have high-level
HER2/CEP17 ratio have shorter TTP and OS than those
with lower ratio, when treated with a trastuzumab-based
regimen. Correlations do not reach the limits of statistical
significance but no formal sample size calculation was
performed due to the explorative nature of the study. If
confirmed in larger cohorts of patients, HER2/CEP17 ratio
could represent a reliable and economical predictor of
response to trastuzumab-based therapy in MBC.
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Introduction
The HER2/neu or c-erbB2 proto-oncogene, located on
chromosome 17q11.2–q21, encodes a growth-factor recep-
tor (HER2) belonging to the class I (epidermal growth
factor) family of tyrosine kinases. Overexpression of the
HER2 receptor, amplification of the HER2/neu gene, or
both, occur in about 20–30% of human breast cancers and
correlate with poor prognosis, including shorter disease-free
survival and overall survival (OS) [1, 2]. Accurate
assessment of HER2 status by determination of HER2
protein overexpression or gene amplification has become an
essential part of management of breast cancer since the
development of trastuzumab (Roche, Basel, Switzerland), a
humanized monoclonal antibody that selectively targets the
extracellular domain of the HER2. Trastuzumab is world-
widely approved as monotherapy or in combination with
chemotherapeutic agents paclitaxel and docetaxel and with
aromatase inhibitors for the treatment of metastatic HER2-
positive breast cancer, it is also approved as adjuvant
therapy for HER2-positive early breast cancer [3–5].
The immunohistochemical technique reveals HER2 pro-
tein overexpression on cell surface, and when used according
to the FDA-approved scoring system, provides a semi-
quantitative estimate HER2 expression [6]. It has emerged
as the method of choice for screening. Fluorescence in situ
hybridization (FISH), which detects gene amplification, is
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often used as a confirmatory test, particularly in cases with
weak positive (score 2+) immunohistochemical results.
Two FDA-approved FISH assays are currently available.
The Inform kit (Ventana Medical Systems, Tucson, AZ,
USA) uses a cosmid probe for the HER2/neu locus and it is
considered positive when the absolute number of gene
copies is >4, but cannot distinguish between true gene
amplification or the presence of more gene copies due to
chromosome 17 polysomy. The PathVysion kit (Abbott-
Vysis, Downers Grove, IL, USA) includes a second probe
for the centromeric region of chromosome 17 (CEP17), so
making it possible to identify true gene amplification. The
PathVysion test is considered positive (HER2 amplified)
when the ratio HER2/CEP17 is ≥2, but this ratio value is
not routinely given in the patient’s report.
HER2/neu amplification, when present in the primary
tumor, is maintained throughout the course of disease and is
an important predictor of response to chemotherapy,
hormonal therapy, and mainly to trastuzumab-based regi-
mens [7–9]. Our experience is that the numerical values of
a positive PathVysion ratio vary widely from 2.1 to over 20.
However the biological and clinical implications of this
variation have not been investigated. To address this, we
performed PathVysion FISH analyses of all patients with
HER2-positive metastatic breast cancer treated at our




This study was designed as a retrospective exploration of
the relationship between level of HER2/neu amplification,
and time to progression (TTP), time to central nervous
system (CNS) progression, and OS. Specific inclusion
criteria were: trastuzumab-based therapy for HER2-positive
metastatic breast cancer; no previous treatment with
trastuzumab, availability of tissue samples from the primary
tumor or a metastatic site, and adequate treatment and
follow-up information. Tests were performed prospectively
on tumor samples archived in the Pathology Department of
our hospital.
Clinical information was retrieved retrospectively from
hospital records and placed in an ad hoc database. In line
with standard procedures, all patients received pretreatment
assessment comprising full blood count, liver and renal
function tests, electrolytes, and baseline computed tomog-
raphy of the chest, abdomen and pelvis, or alternatively,
chest X-ray and ultrasound examination of the abdomen
and pelvis. In conformity with standard policy at both
hospitals, all patients gave written informed consent to the
treatment received. Tumor assessment was performed every
9±1 weeks. Disease response was assessed according to
World Health Organization criteria [10].
Fluorescence in-situ hybridization
The PathVysion kits (Abbott-Vysis) include probes to
determine the number of copies of HER2/neu (spectrum
orange) and the number of CEP17 (spectrum green). Assays
were performed on 3 μm-thick paraffin-embedded tissue
sections, according to the manufacturer’s instruction with the
following minor modifications. Slides were aged three days
at 50°C and dewaxed by washing in Microclearing (DiaPath,
Bergamo, Italy) for 10 minutes twice, followed by incuba-
tion in 1:1 Microclearing/ethanol solution for 10 minutes.
The waxed sections were dehydrated in 100% ethanol for 10
minutes, protease (Proteinase K, Sigma-Aldrich, Saint
Louis, MO, USA) digested for 35 minutes at 50°C and
washed for 3 minutes twice in Phosphate-Buffered Saline
(PBS). Co-denaturation and hybridization then followed in a
HYBrite oven (Abbott-Vysis) according to the manufac-
turer’s protocol.
The FISH determinations were carried out in adherence
to international guidelines by two cytogenetistics experi-
enced in FISH techniques [11]. An Olympus BX 61
fluorescent microscope (Olympus, Tokyo, Japan) equipped
with a Chroma (Rockingham, VT, USA) filter set (DAPI/
spectrum green/spectrum orange/triple band pass) was used
to identify fluorescent signals. Before reviewing the FISH
assay, the areas of invasive tumor, were identified using a
parallel section stained with hematoxylin and eosin. The
number of HER2/neu genes and chromosome 17 signals
was scored between 20 and 60 non-overlapping cells where
possible, using at least three distinct tumor fields. If a total
of at least 20 non-overlapping, intact tumor nuclei could
not be identified in distinct areas of the section, the FISH
test was repeated in other sections of the tumor. In cases
where the ratio was close to 2.0 (between 1.8 and 2.2),
more than 60 cells were counted if possible, or the case
rescored by another qualified observer to ensure the
accuracy of the test results. The mean HER2 to chromo-
some 17 copy ratio was calculated. Tumors with a HER2/
CEP 17 ratio of more than 2 were considered positive for
HER2/neu amplification.
Statistical analysis
TTP was calculated as the time from initiation of
trastuzumab until disease progression or death without
progression, which ever occurred first. Time to CNS
progression was the time from initiation of trastuzumab
until appearance of CNS disease, irrespective of whatever
CNS was the first site of failure. OS was the time from
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initiation of trastuzumab until death for any cause.
Surviving patients were censored on the day of the last
contact. Time to event distributions were estimated using
Kaplan–Meier curves and compared using the log-rank test.
Contingency tables were used to describe distribution of
molecular characteristics and established patient and tumor
characteristics. The Cox proportional hazards models were
used to assess the strength of the association of TTP, time to
CNS progression, and OS and with various clinical and
histological variables. Analysis was explorative in nature
and no formal sample size calculation was performed.
Results
Thirty-five women with HER2-positive metastatic breast
cancer received trastuzumab at Istituto Clinico Humanitas
or Cliniche Gavazzeni between October 2001 and June
2006, and had tumor specimens available for analysis. Two
of these women, both with a 3+ score for HER2 by
immunohistochemistry were excluded as no evidence of
HER2 amplification was found by FISH. The remaining 33
women form the subject of the study. HER2/CEP17 ratio
was assessed for all tumor samples with values ranging
from 2.5 to 21 (median 7.2). The differences in level of
HER2/neu amplification in tumor specimens as evaluated
by FISH test can be observed in a picture at fluorescent
microscope in Fig. 1.
The characteristics of the 33 patients are summarized in
Table 1 together with the HER2/CEP17 ratios. Median age
was 60 years (range: 27–73). Estrogen (ER) and/or
progesterone receptors (PgR) were positive in about 40%.
Trastuzumab was given in combination with chemotherapy
in 27 (82%) patients; whereas 6 (18%) patients received
trastuzumab alone. No patient had received trastuzumab
previously.
Median TTP and OS for all patients were 10.3 and
20.3 months, respectively. CNS progression during
trastuzumab therapy occurred in 7 patients (21%). Figure 2
presents Kaplan–Meier TTP curves for the three subgroups
defined by HER2/CEP17 ratio (<6, 6–10, >10.1). Chosen
cut-offs correspond approximately with sample tertiles and
are presented for displaying the association between level of
HER2/neu amplification and TTP.
At the Cox model, there is indication that the risk of
early progression during a trastuzumab-based therapy
increases with increasing HER2/CEP17 ratio and that cases
with high-level HER2/CEP17 ratio have a shorter TTP that
those with lower ratio (HR=1.07; 95% CI=0.98–1.16; p=
0.154). Cox analysis of HER2/CEP17 ratio suggests an
association with OS (HR=1.08 95% CI=0.98–1.18, p=
0.124) but not with time to CNS progression (HR=1.03
95% CI=0.91–1.16; p=0.645).
Fig. 1 A picture showing the differences in level of HER2/neu gene
amplification in tumor specimens as evaluated by dual-color FISH test
Table 1 Patients characteristics and HER2/CEP17 ratio values
obtained by dual-color FISH test
Number (%)
TOTAL 33











ER and PR negative 19 (58)









Trastuzumab alone 6 (18)
Median HER2/CEP17 ratio (range) 7.2 (2.5–21)
HER2/CEP17 ratio <6 13 (39)
HER2/CEP17 ratio 6–10 11 (33)
HER2/CEP17 ratio >10.1 9 (28)
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Discussion
Trastuzumab is now established in the treatment of HER2-
positive metastatic breast cancer [3–5]. Presence of HER2/
neu gene amplification, as determined by FISH, is signifi-
cantly associated with response to trastuzumab treatment [9].
However, a number of patients with FISH-confirmed HER2-
positive disease fail to respond to trastuzumab, and show
primary or acquired resistance to the antibody. In vitro and in
vivo findings have suggested several reasons for trastuzumab
resistance, involving the phosphorylation of HER2 tyrosine
kinase [12], the signaling pathways associated with the HER
family of receptors [13–16], and the truncated form of HER2
protein [17]. Very recently, a role for the antibody-dependent
cell-mediated cytotoxicity of natural-killer cells/monocytes
has been proposed to explain the differences in response to
trastuzumab-based therapy in metastatic breast cancer [18].
So far, none of these potential predictors of response has
been fully validated and routinely introduced in clinical
practice.
In a previous study we found a significant association
between tumor grade and level of HER2/neu amplification
in a cohort of patients with early stage breast cancer [19]. In
the present study we investigated HER2/neu amplification
using a dual-color FISH test to determine the number of
HER2/neu copies in relation to number of chromosome 17
copies in a small cohort of patients with HER2-positive
metastatic breast cancer receiving trastuzumab. We found
that TTP tended to be shorter in women with high HER2/
CEP17 ratio, although the difference was not statistically
significant. Thus, increasing number of HER2/neu copies
appears to augment the risk of disease progression during
trastuzumab therapy. This finding, which requires confir-
mation on a larger series of patients, suggests that cancers
with a high number of HER2/neu copies may have different
biological behavior compared to cancers with low gene
copy number.
One explanation may be that a high level of amplifica-
tion reflects a more complex genetic pattern and hence the
overall dedifferentiation of a cancer. As might be expected,
comparison of tumor samples representing different stages
of tumor development, such as premalignant or in situ
lesions, invasive cancers, and metastatic disease, has
demonstrated that the overall number of copy increases
during tumor progression. In addition to tumor progression,
the high number of copy number aberrations has also been
linked with poor patient prognosis [20]. Alternatively, high
HER2/neu copy number may indicate activation of redun-
dant trans-membrane signaling pathways that will not be
adequately inhibited by trastuzumab. In both cases a
trastuzumab-based therapy could not reach the same
biological and clinical results observed in patients with a
low-level HER2/neu amplification.
In conclusion, our is the first observation of a possible
relation between level of HER2/neu amplification and TTP
and OS. The most immediate practical implication of our
finding is that the value of the HER2/CEP17 ratio should
always be included in the FISH patient’s report, not only to
facilitate future studies in this area, but also to provide an
indication of likely response to trastuzumab: metastatic
breast cancer patients with high level of HER2/neu ampli-
fication might be at high risk of progression and should be
closely monitored during trastuzumab-based therapy. Addi-
tional studies on larger cohorts of patients are required to
further explore the prognostic implications of level of HER2/
neu amplification in metastatic breast cancer.
Fig. 2 Kaplan–Meier time to
progression curves for the three
subgroups defined by HER2/
CEP17 ratio (< 6, 6–10, >10.1).
At the Cox model, there is
indication that the risk of
early progression during a
trastuzumab-based therapy
increases with increasing HER2/
CEP17 ratio (HR=1.07; 95%
CI=0.98–1.16; p=0.154)
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